[HTML][HTML] Signal transductions and nonalcoholic fatty liver: a mini-review

L Zeng, WJ Tang, JJ Yin, BJ Zhou - International journal of clinical …, 2014 - ncbi.nlm.nih.gov
Nonalcoholic fatty liver disease (NAFLD) is a common liver disease, and the incidence
increases year by year. The pathogenesis of NAFLD is correlated with insulin resistant (IR), and …

Predictive values of body mass index and waist circumference for risk factors of certain related diseases in Chinese adults--study on optimal cut-off points of body …

BF Zhou - Biomedical and environmental sciences: BES, 2002 - europepmc.org
Objective For prevention of obesity in Chinese population, it is necessary to define the optimal
range of healthy weight and the appropriate cut-off points of BMI and waist circumference …

[HTML][HTML] Comparison of ustekinumab and etanercept for moderate-to-severe psoriasis

…, N Yeilding, C Guzzo, Y Xia, B Zhou… - … England Journal of …, 2010 - Mass Medical Soc
Background Biologic agents offer a range of new therapeutic options for patients with
psoriasis; however, the relative benefit–risk profiles of such therapies are not well known. We …

Infliximab improves signs and symptoms of psoriatic arthritis: results of the IMPACT 2 trial

…, C Birbara, A Beutler, C Guzzo, B Zhou… - Annals of the …, 2005 - ard.bmj.com
Objectives: To evaluate further in a phase III, double blind trial the efficacy of infliximab in
patients with active psoriatic arthritis (PsA), as observed in the smaller IMPACT trial. Methods: …

Proportion of different subtypes of stroke in China

LF Zhang, J Yang, Z Hong, GG Yuan, BF Zhou… - Stroke, 2003 - Am Heart Assoc
Background and Purpose— The goal of this article is to clarify the proportion of stroke subtypes
in China, where stoke is the most common cause of death. Methods— A total of 16 031 …

Guselkumab in patients with active psoriatic arthritis who were biologic-naive or had previously received TNFα inhibitor treatment (DISCOVER-1): a double-blind …

…, RA Subramanian, XL Xu, S Sheng, P Agarwal, B Zhou… - The Lancet, 2020 - thelancet.com
Background Many patients with psoriatic arthritis have an inadequate response to tumor
necrosis factor (TNF) inhibitors. Guselkumab, a specific inhibitor of interleukin-23 (IL-23) via IL-…

Guselkumab in biologic-naive patients with active psoriatic arthritis (DISCOVER-2): a double-blind, randomised, placebo-controlled phase 3 trial

…, EC Hsia, XL Xu, S Sheng, P Agarwal, B Zhou… - The Lancet, 2020 - thelancet.com
Background The interleukin-23 (IL-23)/T-helper 17 cell pathway is implicated in psoriatic
arthritis pathogenesis. Guselkumab, an IL-23 inhibitor that specifically binds the IL-23 p19 …

[HTML][HTML] Somatosensory neuron types identified by high-coverage single-cell RNA-sequencing and functional heterogeneity

…, MM Sun, YJ Lu, YQ Zhong, XY Hu, R Hou, BB Zhou… - Cell research, 2016 - nature.com
Sensory neurons are distinguished by distinct signaling networks and receptive characteristics.
Thus, sensory neuron types can be defined by linking transcriptome-based neuron …

Efficacy and safety of ustekinumab, an IL-12 and IL-23 inhibitor, in patients with active systemic lupus erythematosus: results of a multicentre, double-blind, phase 2 …

…, P Lipsky, Z Touma, VP Werth, RM Gordon, B Zhou… - The Lancet, 2018 - thelancet.com
Background Ustekinumab is a monoclonal antibody targeting interleukin (IL)-12 and IL-23
and is approved for the treatment of plaque psoriasis, psoriatic arthritis, and Crohn's disease. …

Recent progress in ceramic matrix composites reinforced with graphene nanoplatelets

BY Zhou, SJ Fan, YC Fan, QI Zheng, X Zhang, W Jiang… - Rare Metals, 2020 - Springer
Graphene nanoplatelets (GNPs) are considered to be one of the most promising new
reinforcements due to their unique two-dimensional structure and remarkable mechanical …